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Full Scientific Report
Introduction
Neoplasia of the spinal cord is typically subdivided based on 
their location of origin: extradural, intradural–extraparen-
chymal, or intraparenchymal. Tumors in cats that arise within 
the intradural space are the most common and include lym-
phoma, meningioma, and histiocytic sarcoma.2,10,14,18 Intra-
parenchymal neoplasia is much less commonly recorded in 
cats and includes tumors that arise from glial cells (or their 
progenitors), including astrocytes, oligodendrocytes, epen-
dymal cells, and microglial cells. Although the histologic 
appearance of many oligodendrogliomas and ependymomas 
are fairly uniform, tumors of astrocytic origin can have a 
markedly wide spectrum of histologic appearance and 
include fibrillary, protoplasmic, pilocytic, gemistocytic, 
astroblastic, and granular cell variants. Additionally, owing 
to the common cellular origin of some astrocytes and oligo-
dendrocytes, tumors can exhibit differentiation toward both 
cell lineages.
In the cat, extraparenchymal lymphoma and osteosar-
coma are reported to be the most common tumors affecting 
the spinal cord whereas intraparenchymal neoplasia is 
uncommon with only brief case reports of astrocytomas and 
oligodendrogliomas.5,11,19,20 A 2008 retrospective study 
detailing spinal neoplasia in cats reported low numbers 
(8/85) of cats affected by intraparenchymal spinal neopla-
sia.11 Because of the relative lack of knowledge in regard to 
intraparenchymal spinal cord tumors in cats, the present 
retrospective study was initiated to better describe the clini-
cal presentations, magnetic resonance imaging (MRI) find-
ings, pathologic, and immunohistochemical features of a 
cohort of cats with intraparenchymal spinal cord neoplasms.
Materials and methods
The pathology database at Cornell University College of Vet-
erinary Medicine (Ithaca, New York) was searched for cases 
of spinal cord neoplasia in the cat from the period of 1980–
2012. All cases were reviewed by 2 board-certified veteri-
nary anatomic pathologists (Miller and Summers). Four of 7 
cases were studied at necropsy (Cornell University) while 
the remainder was submitted by referring board-certified 
veterinary neurologists. All necropsies were performed 
within 6 hours of death. Tissues were collected, fixed in 10% 
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Abstract. Intraparenchymal spinal cord tumors in the cat are rarely reported and often as single case reports. In the 
current study, the clinical, magnetic resonance imaging (MRI), histologic, and immunohistochemical features of 7 cases of 
intraparenchymal spinal cord tumors in the cat are described. All cats were domestic breed, ranged from 4 to 12 years of age 
(median 8 years), and included spayed females (5/7) and neutered males (2/7). The duration of clinical signs ranged from 2 
weeks to 3 months. MRI revealed lesions that were hyperintense on T2-weighted images with variable contrast enhancement. 
All 7 tumors had histologic features consistent with glial origin: 3 were astrocytic (gemistocytic or fibrous), and 2 were 
oligoastrocytic. Single cases of oligodendroglioma and gliomatosis cerebri were also present in the study. Glial fibrillary 
acidic protein immunoreactivity was robust in the tumors that were predominately astrocytic, and the gliomatosis cerebri case 
had extensive BLA.36 and Iba1 immunoreactivity. Ki-67 immunoreactivity was variable and most abundant in the case of 
malignant oligoastrocytoma. The majority of peritumoral lymphocytes were CD3 positive. The current study expands upon 
the known reports of spinal cord neoplasia in the cat, confirms a caudal cervical segment predilection, and includes a report of 
gliomatosis cerebri in the spinal cord of a cat.
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neutral buffered formalin, embedded in paraffin, sectioned at 
5 µm, and stained using hematoxylin and eosin.
In 6 out of the 7 cases, immunohistochemical staining 
(IHC) using an automated platform was performed.a One 
case did not have enough material to perform IHC (case 3). 
The antibodies used included: glial fibrillary acidic protein 
(GFAPb; 1:5,000 dilution), Ki-67b (1:50 dilution), BLA.36c 
(1:600 dilution), MAC)387b (1:300 dilution), Pax-5a (ready 
to use), cluster of differentiation (CD)45d (1:100), and CD3a 
(ready to use). Detection was achieved through either the 
polymer refine DAB (3,3’-diaminobenzidine) kita (CD3, 
BLA.36, Ki-67, and CD45) or the polymer refine red kita 
(GFAP, MAC387, and PAX-5). Negative controls consisted 
of phosphate buffered saline substitution for the primary 
antibody. Positive control tissues consisted of lymph node 
(CD3, BLA.36, PAX-5, MAC387, Ki-67, and CD45) and 
brain (GFAP). Additional IHC for Iba1e was performed 
under the following conditions: formalin-fixed, paraffin-
embedded sections were deparaffinized, rehydrated, and 
subsequently blocked with hydrogen peroxide. Pretreatment 
involved microwaving for 20 min in 0.01 M citrate buffer 
followed by 20 min of cooling. All steps were followed by a 
Tris-buffered saline wash. Prior to application of primary 
antibodies, all slides were treated with protein blockb for 10 
min. Sections were incubated with anti-rabbit Iba1 (poly-
clonal, 1:1,000, 30 min at room temperature). Slides were 
then incubated with secondary antibody biotinylated goat 
anti-rabbitf (1:200, 30 min at room temperature) followed by 
30-min incubation at room temperature with a commercial 
avidin–biotin–peroxidase complex kit.e The Iba1 slides were 
developed with DAB chromogenb and counterstained with 
Mayer hematoxylin. GFAP is an intermediate filament and is 
used to identify cells of astrocytic origin. Ki-67 is a prolif-
eration marker and can be used to derive the labeling index 
within a tumor (the number of Ki-67–positive cells divided 
by total number of cells). BLA.36 is predominately expressed 
by B-lymphocytes and their progenitors; however, it is also 
known to recognize dendritic cells including microglia 
(Miller, personal observation, 2013).13 MAC387 is expressed 
predominately on blood monocytes and tissue macrophages. 
PAX-5 is a transcription factor expressed through B-cell 
maturation. CD3 is a membrane antigen that stains T-lym-
phocytes. CD45 is a transmembrane glycoprotein involved 
in T-cell and B-cell receptor signaling. Iba1 is an ionized 
calcium-binding adapter molecule that is expressed on 
microglia.
Results
Clinicopathologic features
Seven cats were included in the present study. Five of the 7 
cats were Domestic Shorthair, and 2 were Domestic Long-
hair. Five of the 7 were spayed females and 2 were neutered 
males. Ages ranged from 4 to 12 years of age with a median 
age of 8 years. The duration of clinical signs ranged from 2 
weeks to 3 months. Details of signalment, clinical signs, and 
neuroimaging results are noted in Table 1. Ancillary testing 
(complete blood cell count, chemistry, urinalysis, cerebro-
spinal fluid analysis, and serology) was normal except for 
Feline leukemia virus serology, which was positive for case 
5. Clinical features and neuroimaging results are noted in 
Table 1. Animals were either treated with corticosteroids for 
2–4 weeks prior to euthanasia (cases 1 and 2) or were eutha-
nized at time of diagnosis (cases 3–7). No improvement was 
noted in the animals treated with corticosteroids.
Gross, histologic, and immunohistochemical 
features
Gross and histologic features are detailed in Table 2. In 3 out 
of 7 cats, the lesion resulted in a visible, segmental enlargement 
Table 1. Clinicopathologic features of spinal gliomas in 7 cats.*
Case 
no.
Age 
(years) Breed Sex
Duration of clinical 
signs (weeks)
Neuroanatomic 
diagnosis Neuroimaging
1 12 DSH FS 12 C6-T2 MRI: intraparenchymal lesion at level of C4; hyperintense 
on T2WI, isointense on T1WI; slight contrast 
enhancement
2 11.5 DLH MN 2 T3-L3 Spinal radiographs and MRI: normal
3 6 DSH FS 6 Nonspecific pain Myelogram: intraparenchymal mass C5-T1
4 4 DSH FS 2 L4-S1 None
5 11 DLH FS 8 C6-T2 Myelogram: intraparenchymal mass from C6-T4
6 7 DSH FS 12 T3-L3 MRI: intraparenchymal lesion at the level of T13; 
hyperintense on T2WI and FLAIR; hypointense on 
T1WI; scant ring enhancement
7 8 DSH MN 2 C1-C5 MRI: suspect extraparenchymal mass at C5; hyperintense 
on T2WI, isointense on T1WI; strongly contrast 
enhancing
* DSH = Domestic Shorthair; DLH = Domestic Longhair; FS = female, spayed; MN = male, neutered; MRI = magnetic resonance imaging; T1WI = T1-
weighted image; T2WI = T2-weighted image; FLAIR = fluid-attenuated inversion recovery.
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of the spinal cord. On transverse section, lesions consisted of 
an intraparenchymal, yellow-tan, expansile mass with no 
discernible borders with normal parenchyma.
Histologically, all tumors displayed behavior consistent 
with cells of glial origin. All tumors effaced spinal cord 
structures; however, no invasion into the subarachnoid space, 
through the dura, or into nerve roots was noted. Tumors were 
predominately located in the gray matter in cases 4 and 5, 
white matter in case 1, mixed gray and white matter in cases 
3 and 7, and was diffuse in case 2. Microscopically, the 
tumors were well demarcated in cases 3, 6, and 7. In the 
remaining cases, regions of extensive invasion into the adja-
cent, less-affected white matter resulted in myelin loss with 
the formation of digestion chambers (ellipsoids) containing 
invading macrophages with disintegration and loss of axons. 
Large gemistocytic astrocytes (as part of pure astrocytomas 
or mixed gliomas) were the predominant astrocyte pheno-
type in 4 of the 7 animals (cases 1, 3, 5, and 7; Fig. 1A). In 
these cases, the gemistocytes, with abundant eosinophilic 
cytoplasm and eccentrically located nuclei, were often 
arranged in loose aggregates and cords and were interspersed 
with fine, often fibrillary eosinophilic matrix. There was lit-
tle cellular and nuclear atypia in this population of cells. Two 
cases (nos. 1 and 5) had regions of more atypical growth 
where astrocytes formed ill-defined sheets with occasional 
pseudorosettes and showed marked cellular and nuclear 
atypia (Fig. 1B). The mitotic rate in these areas was greater 
than 3–5 per 400× field. Case 4 was a small mass composed 
of small fibrous astrocytes that had mild to moderate amounts 
of eosinophilic cytoplasm and blended seamlessly with the 
adjacent parenchyma.
One case (no. 6) had diffuse infiltration of the paren-
chyma by small round cells with hyperchromatic nuclei and 
inapparent cytoplasm, resembling a “fried egg” appear-
ance, consistent with an oligodendroglioma (Fig. 1C). 
These neoplastic cells lacked apparent atypia, and no mito-
ses were noted. Cases 1 and 5 also had small foci of oligo-
dendroglial differentiation comprising roughly 30–40% of 
the tumor population. The oligodendroglial component of 
these 2 cases had prominent atypia with 2–4 mitotic figures 
per 400× field.
Finally, case 2 had extensive and diffuse invasion of the 
white and gray matter by neoplastic glial cells that had inap-
parent cytoplasm and elongate to angular nuclei histomor-
phologically resembling microglial cells (Fig. 1D). These 
neoplastic cells displayed moderate atypia. There was mod-
erate anisocytosis and anisokaryosis, and the mitotic rate was 
1–3 per 400× field. Within some areas of the white matter, 
neoplastic cells extended to the subpial region. In the gray 
matter, there were foci of neuronal satellitosis by the neo-
plastic cells.
Inflammation was present in 6 out of 7 cases (nos. 1–3, 
5–7) and consisted of perivascular aggregates of small lym-
phocytes. The inflammatory foci were typically concentrated 
around the periphery of the neoplasms; however, scattered 
foci of intratumoral inflammation were noted. Reactive 
blood vessels were noted in all cases; however, glomeruloid 
blood vessels suggestive of malignancy were only noted in 
case 1.
Immunohistochemically, 4 of 6 cases had immunoreactiv-
ity for GFAP. Cases 4 and 7 had diffuse cytoplasmic immu-
noreactivity consistent with their histologic features of pure 
astrocytomas (Fig. 2A). As expected, cases 1 and 5 stained 
uniformly positive for GFAP in astrocytic areas whereas 
areas of oligodendroglial development displayed either scant 
or absent immunoreactivity (Fig. 2B). No GFAP immunore-
activity was noted in cases 2 and 6. Ki-67 immunoreactivity 
was varied (see Table 2) and was most abundant in case 5 
(malignant oligoastrocytoma; Fig. 2C). Ki-67 immunoreac-
tivity was scattered in cases 1 and 7 and was not noted in 
cases 2, 4, and 6. Case 2, which was negative for GFAP and 
Ki-67, had strong cytoplasmic immunoreactivity for BLA.36 
(but negative for PAX-5 and CD45; Fig. 2D). Roughly 75% 
of the neoplastic cells in case 2 were also strongly positive 
for Iba1 (Fig. 2D, inset). Tumor-associated inflammation 
was assessed with CD3, MAC387, and PAX-5. Variable, 
scattered infiltrates of CD3-positive cells (average 2–5 per 
400× field) were noted in and around the tumor in 5 out of 
Table 2. Gross, histologic, and select immunohistochemical features of spinal cord gliomas in the cat.*
Case no. Gross lesions Location Diagnosis
Ki-67 immunoreactivity 
(% positive cells)
GFAP 
immunoreactivity
1 Yes C4/C5 Oligoastrocytoma 5–10 +
2 No Caudal thoracic Gliomatosis cerebri 0 –
3 No C7 Gemistocytic 
astrocytoma
NA NA
4 No Proximal lumbar Fibrous astrocytoma 0 +
5 No C6-T4 Malignant 
oligoastrocytoma
>50 +
6 Yes T13 Oligodendroglioma 0 –
7 Yes C6 Gemistocytic 
astrocytoma
5–10 +
* GFAP = glial fibrillary acidic protein; NA = not applicable.
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6 cases. Three of 6 cases had rare MAC387-positive macro-
phages. Only 1 case (no. 7) had a single perivascular cuff of 
PAX-5–positive lymphocytes.
Discussion
Reports of neoplasms of the feline central nervous system 
largely describe tumors that arise adjacent to the brain and 
spinal cord with few reports concentrated on intraparenchy-
mal neoplasia. In a 2008 retrospective report of spinal neo-
plasia in the cat, lymphoma accounted for almost 39% of 
neoplasia affecting the spinal cord whereas only approxi-
mately 9% of reported tumors were glial in origin.11 Of the 
glial tumors in that report, 3 out of 8 were astrocytomas, 2 
were ependymomas, and 6 cases were located within the cer-
vical portion of the spinal cord.11 In the current report, 4 out 
of the 7 cases involved the caudal cervical spinal cord with 
the other 3 located in either the thoracic or lumbar regions. 
Although reported cases are few, there may be an increased 
likelihood for intraparenchymal spinal cord tumors in the cat 
to arise in the cervical spinal cord.
In the current report, astrocytic tumors were the most fre-
quently reported. This is consistent with the previous litera-
ture. Both fibrous and gemistocytic variants of astrocytoma 
were noted. Gemistocytes are a common astrocyte pheno-
type that can predominate in both reparative and neoplastic 
lesions. Although not relevant for clinical staging, a differen-
tial diagnosis for a gemistocytic astrocytoma is the giant cell 
astrocytoma.4 Unlike the tumors described herein (and even 
less common), giant cell astrocytomas arise in a subventricu-
lar location and have diffuse distribution of the gemistocytes. 
In addition, the giant cell variant tends to be more circum-
scribed rather than blending seamlessly with the adjacent 
parenchyma as did the gemistocytic variants reported in the 
current case series.
Three of the cases had features of oligodendroglial dif-
ferentiation with 2 diagnosed as mixed oligoastrocytoma. 
Oligoastrocytomas, well recognized in human beings, are 
Figure 1. Feline spinal glioma. A, gemistocytic astrocytoma with ill-defined sheets of neoplastic gemistocytes, case 3. Hematoxylin 
and eosin (HE). Bar = 50 µm. B, malignant oligoastrocytoma with pseudorosette formation, case 5. HE. Bar = 20 µm. C, oligodendroglioma 
with sheets of polygonal to round cells arranged in a honeycomb-like lattice, case 6. HE. Bar = 50 µm. D, gliomatosis cerebri with diffuse 
infiltration of the gray and white matter by neoplastic glial cells, case 2. HE. Bar = 100 µm. Inset: neoplastic cells have elongate to slightly 
angular nuclei with moderate atypia, case 2. HE. Bar = 10 µm.
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thought to arise from a multipotential progenitor cell that 
undergoes malignant transformation and can develop dually 
into astrocytic and oligodendrocytic cell lines.17 Although 
some degree of dual astrocytic and oligodendrocytic differ-
entiation in glial tumors occurs commonly, the diagnosis of 
oligoastrocytoma requires at least 30% of the tumor be com-
prised by one of the neoplastic cell populations. It is thought 
that these multipotential progenitor cells reside in the subep-
endymal rests and can give rise to neoplasms that have var-
ied histologic appearance based on the section examined. 
Judging the malignancy of gliomas based on histologic 
examination can be difficult; however, the presence of glo-
meruloid blood vessels, increased atypia, and robust Ki-67 
immunoreactivity are all suggestive of increased malignancy 
(and was variably present in cases 1 and 5).15,20
While histologic features remain the most reliable way to 
accurately diagnose neoplasia of the central nervous system, 
ancillary testing like IHC can aid greatly in diagnosis. GFAP, 
an intermediate filament largely of astrocytes and a reliable 
immunohistochemical marker, was positive in 4 out of 6 
cases consistent with the histologic features. Immunohisto-
chemical diagnosis of oligodendrogliomas remains less 
consistent as markers such as Olig2 can stain both oligoden-
drocytes and astrocytes and cannot be relied on as the sole 
criterion for making a diagnosis.6 Interestingly, in the current 
report, case 2 had no immunoreactivity for GFAP, but did 
have strong immunoreactivity for BLA.36.16 BLA.36 is a 
leukocyte marker that can be used to stain B-lymphocytes 
and also is known to stain epidermal dendritic cells.13 To the 
authors’ knowledge, BLA.36 has not previously been used to 
diagnose central nervous system tumors; however, it has 
strong immunoreactivity with normal feline microglia (data 
not shown). In addition, the majority of neoplastic cells in 
case 2 were strongly positive for Iba1 further suggesting 
Figure 2. Feline spinal cord glioma. A, gemistocytic astrocytoma with marked glial fibrillary acidic protein (GFAP) immunoreactivity, 
case 7. 3,3′-diaminobenzidine (DAB) chromogen with Mayer hematoxylin counterstain. Bar = 50 µm. B, malignant oligoastrocytoma 
revealing regions of oligodendroglioma differentiation that lack GFAP immunoreactivity, case 5. DAB chromogen with Mayer hematoxylin 
counterstain. Bar = 100 µm. C, marked Ki-67 immunoreactivity in malignant oligoastrocytoma, case 5. Leica red chromogen with Mayer 
hematoxylin counterstain. Bar = 20 µm. D, diffuse immunoreactivity for BLA.36 in gliomatosis cerebri, case 2. DAB chromogen with Mayer 
hematoxylin counterstain. Bar = 50 µm. Inset: approximately 75% of the neoplastic cells have variably intense cytoplasmic immunoreactivity 
for Iba1, case 2. DAB chromogen with Mayer hematoxylin counterstain. Bar = 10 µm.
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microglial origin. This case also failed to display immunore-
activity with either PAX-5 or CD45 indicating that this tumor 
was likely not of lymphocyte origin. Although the cell of ori-
gin in gliomatosis cerebri remains controversial, in most 
human cases it is believed to be derived from astrocytes; 
however, based on the microscopic and immunohistochemi-
cal features of the case presented herein, this represents an 
extremely uncommon variant of gliomatosis cerebri derived 
from microglia.
In the current study, the median age at diagnosis was 8 
years (6/7 cases were aged 6 years or older) with the average 
duration of clinical signs between 2 weeks to 3 months. In 5 
of 7 cases, the owners elected euthanasia at time of diagno-
sis based on the presumed poor long-term prognosis. The 2 
patients treated with steroids were euthanized 2 weeks later 
because of a poor response to therapy. Treatment of intra-
parenchymal tumors is limited. No known reports exist in 
the veterinary literature of surgical therapy for spinal glial 
tumors in the cat. In human medicine, therapy is controver-
sial and includes dural decompression, radiation therapy, 
and radical excision of the tumors.3,8 Aggressive surgical 
therapy is rarely considered in veterinary medicine because 
of the concern of neurologic deterioration postoperatively. 
However, radical surgical excision has not been shown to 
cause significant clinical worsening in human beings and 
thus may be a consideration for veterinary patients with 
well-defined intraparenchymal tumors found to be well 
defined with MRI. Outcome after radical excision in human 
beings depends on tumor grade and neurologic status prior 
to surgery. In addition, intraoperative monitoring, such as 
evoked potentials, intraoperative ultrasound, ultrasonic 
aspirator, and surgical microscopes have been shown to be 
beneficial in defining the safe extent of resection during sur-
gery in people. Owing to the invasive nature of these neo-
plasms (observed grossly and microscopically in the cases 
reported herein), the benefit of surgical resection is likely 
low. Little is known about the response rate with radiation 
therapy, chemotherapy, or multimodal therapy, and it is 
likely that treatment options will vary based on a variety of 
tumor-related characteristics (i.e., proliferative fraction, 
degree of invasiveness, etc.).
Magnetic resonance imaging enables localization of spi-
nal cord tumors in relationship to the dura as extradural, 
intradural-extraparenchymal, or intraparenchymal tumors. 
An accurate anatomic diagnosis not only provides the clini-
cian the ability to form a list of differentials based on loca-
tion of the lesion, but also allows for more specific 
diagnostics and treatment options. MRI has been reported to 
accurately diagnose the location of spinal cord tumors in 
human beings. However, limited reports are available on the 
MRI of spinal cord tumors in dogs and cats.1,9,12,21 Some 
characteristics of intraparenchymal tumors include enlarge-
ment of the spinal cord on multiple planes, thinning of the 
subarachnoid space at the level of the lesion, and contrast 
enhancement within the spinal cord.7 In the current case 
series, 4 out of 7 patients had MRI in order to characterize 
the cause of the neurological dysfunction. In these cases, 
MRI accurately determined the intraparenchymal location 
of the tumor in 3 cats. In 1 cat, the lesion was thought to be 
extradural. Lesions were hyperintense on T2-weighted 
image (T2WI) in 3 out of 4 cases. Additionally, 3 out of 4 of 
the lesions had minimal contrast enhancement or ring 
enhancement as is classically seen with intracranial tumors 
of glial origin (Fig. 3). Table 3 presents a comparison of 
imaging findings based on tumor location. Despite these cri-
teria, definitive anatomic localization can be difficult, espe-
cially between the parenchymal and extraparenchymal 
compartments. Reasons for difficulty in determining the 
correct anatomic space include poor spatial resolution due 
to size of spinal cord, prevention of cerebrospinal fluid 
Figure 3. Feline spinal cord glioma. A, case 7, sagittal T2-weighted image (T2WI; repetition time [TR] = 3,000; echo time [TE] = 117). 
A poorly defined T2 hyperintense region is present in the caudal cervical spinal cord surrounding an isointense mass (arrow). B, case 7, 
sagittal fast spoiled gradient-echo (FSPGR) after contrast medium administration (TR = 150; TE = 6; α = 70). The mass is strongly contrast 
enhancing with a central nonenhancing region (field of view [FOV] = 18 × 12, thickness = 2 mm, spacing = 2.5 mm, matrix = 256 × 256).
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pooling between the mass and spinal cord, and invasiveness 
of the tumor.
The current retrospective study further advances the litera-
ture regarding intraparenchymal spinal cord tumors in cats. 
Although this cohort of cases was small, a clear breed or sex 
predilection (5/7 female) was not observed. Likewise, despite 
the paucity of reported cases, these tumors may have a predi-
lection for the cervical spinal cord with the majority having an 
astrocytic morphology. Oligodendrocytic and mixed astro-
cytic–oligodendrocytic neoplasms may also be observed. MRI 
can greatly aid in the diagnosis and better direct the clinician 
to the cause of the neurologic signs in the affected animal.
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Table 3. General patterns for localization of spinal neoplasia based on magnetic resonance imaging.*
Intraparenchymal Extraparenchymal/intradural Extradural
CSF signal Thinning of subarachnoid space 
at the level of the lesion
“Golf tee” sign Gradual tapering of CSF; CSF column 
displaced away from vertebral arch or body
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Additional comments Broad base along meninges; 
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* CSF = cerebrospinal fluid; SAS = subarachnoid space.
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